DRUG:AU:AU-BetaShares Global Healthcare Currency Hedged (AUD)

ETF | Others |

Last Closing

USD 8.99

Change

0.00 (0.00)%

Market Cap

USD 0.17B

Volume

0.04M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-14 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

+0.22 (+0.22%)

USD 16.05B
VGS:AU Vanguard MSCI International Sh..

-0.21 (-0.17%)

USD 8.59B
IVV:AU iShares Core S&P 500 AUD

-0.11 (-0.20%)

USD 8.26B
QUAL:AU VanEck Vectors MSCI World ex A..

-0.11 (-0.20%)

USD 6.31B
IOZ:AU Ishares Core S&P/Asx 200

+0.10 (+0.30%)

USD 5.96B
STW:AU SPDR® S&P/ASX 200 Fund

+0.21 (+0.28%)

USD 5.61B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

-0.13 (-0.33%)

USD 4.86B
NDQ:AU Betashares Nasdaq 100

-0.32 (-0.74%)

USD 4.83B
A200:AU BetaShares Australia 200

+0.39 (+0.28%)

USD 4.72B
VTS:AU Vanguard US Total Market Share..

-1.01 (-0.24%)

USD 4.70B

ETFs Containing DRUG:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.51% 81% B- 75% C
Dividend Return 3.15% 61% D- 52% F
Total Return 16.66% 83% B 76% C+
Trailing 12 Months  
Capital Gain 12.80% 70% C- 72% C
Dividend Return 3.13% 45% F 37% F
Total Return 15.93% 70% C- 72% C
Trailing 5 Years  
Capital Gain 52.63% 88% B+ 79% B-
Dividend Return 10.93% 46% F 34% F
Total Return 63.56% 85% B 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 6.94% 77% C+ 58% F
Dividend Return 8.47% 74% C 57% F
Total Return 1.53% 50% F 31% F
Risk Return Profile  
Volatility (Standard Deviation) 8.36% 67% D+ 93% A
Risk Adjusted Return 101.28% 97% N/A 98% N/A
Market Capitalization 0.17B 34% F 66% D+

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.